Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
J. appl. oral sci ; 20(2): 128-138, Mar.-Apr. 2012. ilus, tab
Article in English | LILACS | ID: lil-626410

ABSTRACT

Recently, new treatment approaches have been developed to target the host component of periodontal disease. This review aims at providing updated information on host-modulating therapies, focusing on treatment strategies for inhibiting signal transduction pathways involved in inflammation. Pharmacological inhibitors of MAPK, NFκB and JAK/STAT pathways are being developed to manage rheumatoid arthritis, periodontal disease and other inflammatory diseases. Through these agents, inflammatory mediators can be inhibited at cell signaling level, interfering on transcription factors activation and inflammatory gene expression. Although these drugs offer great potential to modulate host response, their main limitations are lack of specificity and developments of side effects. After overcoming these limitations, adjunctive host modulating drugs will provide new therapeutic strategies for periodontal treatment.


Subject(s)
Humans , Inflammation Mediators/antagonists & inhibitors , Intracellular Signaling Peptides and Proteins/therapeutic use , Molecular Targeted Therapy/methods , Periodontal Diseases/therapy , Signal Transduction/drug effects , Biofilms , Inflammation Mediators/immunology , Inflammation Mediators/metabolism , Intracellular Signaling Peptides and Proteins/immunology , Janus Kinases/immunology , Janus Kinases/metabolism , Mitogen-Activated Protein Kinases/immunology , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/immunology , NF-kappa B/metabolism , Periodontal Diseases/etiology , Periodontal Diseases/immunology , STAT Transcription Factors/immunology , STAT Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL